Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women
Approximately 40% of human pregnancies are unintended, indicating a need for more acceptable effective contraception methods. New antibody production systems make it possible to manufacture reagent-grade human monoclonal antibodies (mAbs) for clinical use. We used the Nicotiana platform to produce a human antisperm mAb and tested its efficacy for on-demand topical contraception.
EpiVaginal (VEC-100-FT), human sperm, anti-sperm monoclonal antibody, human complement, contraception antibody, IgG1, VRC01-N, anti-HIV IgG1 mAb, contraception, proinflammatory cytokines, apical and basolateral cytokine secretion, IL-1RA, IL-1a, IL-1b, IL-6, IL-8, MCP-1
human sperm, anti-sperm monoclonal antibody, VRC01-N, anti-HIV IgG1 monoclonal antibody
Request a copy of this paper, click here.